1. |
Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost, 2007, 5(4): 692-699.
|
2. |
Spencer FA, Gore JM, Lessard D, et al. Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost, 2008, 100(5): 780-788.
|
3. |
Tagalakis V, Patenaude V, Kahn SR, et al. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med, 2013, 126(9): 832.
|
4. |
Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med, 2000, 160(6): 761-768.
|
5. |
LaMori JC, Shoheiber O, Mody SH, et al. Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States. Clin Ther, 2015, 37(1): 62-70.
|
6. |
Silverstein RL, Bauer KA, Cushman M, et al. Venous thrombosis in the elderly: more questions than answers. Blood, 2007, 110(9): 3097-3101.
|
7. |
Link RP. National heart, lung, and blood institute programs for deep vein thrombosis. Arterioscler Thromb Vasc Biol, 2008, 28(3): 392-393.
|
8. |
Méan M, Righini M, Jaeger K, et al. The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology. J Thromb Thrombolysis, 2013, 36(4): 475-483.
|
9. |
Poli D, Antonucci E, Testa S, et al. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation, 2011, 124(7): 824-829.
|
10. |
Spencer FA, Gurwitz JH, Schulman S, et al. Venous thromboembolism in older adults: a community-based study. Am J Med, 2014, 127(6): 530-537.
|
11. |
López-Jiménez L, Montero M, González-Fajardo JA, et al. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica, 2006, 91(8): 1046-1051.
|
12. |
Folsom AR, Boland LL, Cushman M, et al. Frailty and risk of venous thromboembolism in older adults. J Gerontol A Biol Sci Med Sci, 2007, 62(1): 79-82.
|
13. |
Ageno W, Agnelli G, Imberti D, et al. Risk factors for venous thromboembolism in the elderly: results of the master registry. Blood Coagul Fibrinolysis, 2008, 19(7): 663-667.
|
14. |
Di Minno G, Mannucci PM, Tufano A, et al. The first ambulatory screening on thromboembolism: a multicentre, cross-sectional, observational study on risk factors for venous thromboembolism. J Thromb Haemost, 2005, 3(7): 1459-1466.
|
15. |
Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost, 2010, 8(10): 2105-2112.
|
16. |
Mohebali D, Kaplan D, Carlisle M, et al. Alterations in platelet function during aging: clinical correlations with thromboinflammatory disease in older adults. J Am Geriatr Soc, 2014, 62(3): 529-535.
|
17. |
Kucher N, Leizorovicz A, Vaitkus PT, et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med, 2005, 165(3): 341-345.
|
18. |
Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med, 2004, 164(9): 963-968.
|
19. |
Greig MF, Rochow SB, Crilly MA, et al. Routine pharmacological venous thromboembolism prophylaxis in frail older hospitalised patients: where is the evidence? Age Ageing, 2013, 42(4): 428-434.
|
20. |
Decousus H, Tapson VF, Bergmann JF, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest, 2011, 139(1): 69-79.
|
21. |
Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med, 1999, 341(11): 793-800.
|
22. |
Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation, 2004, 110(7): 874-879.
|
23. |
Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ, 2006, 332(7537): 325-329.
|
24. |
Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2 Suppl): e195S-e226S.
|
25. |
Le Gal G, Righini M, Roy PM, et al. Differential value of risk factors and clinical signs for diagnosing pulmonary embolism according to age. J Thromb Haemost, 2005, 3(11): 2457-2464.
|
26. |
Bajaj N, Bozarth AL, Guillot J, et al. Clinical features in patients with pulmonary embolism at a community hospital: analysis of 4 years of data. J Thromb Thrombolysis, 2014, 37(3): 287-292.
|
27. |
Piazza G, Seddighzadeh A, Goldhaber SZ. Deep-vein thrombosis in the elderly. Clin Appl Thromb Hemost, 2008, 14(4): 393-398.
|
28. |
Oger E, Bressollette L, Nonent M, et al. High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients. Thromb Haemost, 2002, 88(4): 592-597.
|
29. |
Siccama RN, Janssen KJ, Verheijden NA, et al. Systematic review: diagnostic accuracy of clinical decision rules for venous thromboembolism in elderly. Ageing Res Rev, 2011, 10(2): 304-313.
|
30. |
Righini M, Le Gal G, Perrier A, et al. Effect of age on the assessment of clinical probability of pulmonary embolism by prediction rules. J Thromb Haemost, 2004, 2(7): 1206-1208.
|
31. |
Di Nisio M, Squizzato A, Rutjes AW, et al. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost, 2007, 5(2): 296-304.
|
32. |
Lucassen W, Geersing GJ, Erkens PM, et al. Clinical decision rules for excluding pulmonary embolism: a meta-analysis. Ann Intern Med, 2011, 155(7): 448-460.
|
33. |
Geersing GJ, Zuithoff NP, Kearon C, et al. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ, 2014, 348: g1340.
|
34. |
Bates SM, Jaeschke R, Stevens SM, et al. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2 Suppl): e351S-e418S.
|
35. |
Righini M, Goehring C, Bounameaux H, et al. Effects of age on the performance of common diagnostic tests for pulmonary embolism. Am J Med, 2000, 109(5): 357-361.
|
36. |
Eichinger S, Heinze G, Kyrle PA. D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model. J Am Heart Assoc, 2014, 3(1): e000467.
|
37. |
Tritschler T, Méan M, Limacher A, et al. Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model. Blood, 2015, 126(16): 1949-1951.
|
38. |
Castellucci LA, Cameron C, Le Gal G, et al. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. JAMA, 2014, 312(11): 1122-1135.
|
39. |
Chai-Adisaksopha C, Crowther M, Isayama T, et al. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood, 2014, 124(15): 2450-2458.
|
40. |
MacLean S, Mulla S, Akl EA, et al. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2 Suppl): e1S-e23S.
|
41. |
Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA, 2014, 311(11): 1117-1124.
|
42. |
Howard LS, Huqhes RJ. National institute for health and clinical excellence, venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. London: Oxford, 2012: 235-246.
|
43. |
Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J, 2014, 35(43): 3033-3069.
|
44. |
Kellum JA, Aspelin P, Barsoum RS, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int, 2012, 2(Suppl):1-138.
|
45. |
Gasparini A, Evans M, Coresh J, et al. Prevalence and recognition of chronic kidney disease in Stockholm healthcare. Nephrol Dial Transplant, 2016, 31(12): 2086-2094.
|
46. |
Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis, 2003, 41(1): 1-12.
|
47. |
Kooiman J, Sijpkens YW, van Buren M, et al. Randomised trial of no hydration vs. sodium bicarbonate hydration in patients with chronic kidney disease undergoing acute computed tomography-pulmonary angiography. J Thromb Haemost, 2014, 12(10): 1658-1666.
|
48. |
Ikesaka R, Carrier M. Clinical significance and management of subsegmental pulmonary embolism. J Thromb Thrombolysis, 2015, 39(3): 311-314.
|
49. |
Di Minno MN, Ambrosino P, Dentali F. Safety of warfarin in " high-risk” populations: a meta-analysis of randomized and controlled trials. Thromb Res, 2017, 150: 1-7.
|
50. |
van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood, 2014, 124(12): 1968-1975.
|
51. |
Bajc M, Neilly JB, Miniati M, et al. EANM guidelines for ventilation/perfusion scintigraphy: part 1. Pulmonary imaging with ventilation/perfusion single photon emission tomography. Eur J Nucl Med Mol Imaging, 2009, 36(8): 1356-1370.
|
52. |
Levi M, Hovingh GK, Cannegieter SC, et al. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood, 2008, 111(9): 4471-4476.
|
53. |
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest, 2016, 149(2): 315-352.
|
54. |
Aujesky D, Smith KJ, Roberts MS. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event. Am J Med, 2005, 118(6): 625-635.
|
55. |
Poli D, Antonucci E, Testa S, et al. The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study. J Thromb Haemost, 2013, 11(6): 1053-1058.
|
56. |
Scherz N, Méan M, Limacher A, et al. Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism. J Thromb Haemost, 2013, 11(3): 435-443.
|
57. |
Leiss W, Méan M, Limacher A, et al. Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. J Gen Intern Med, 2015, 30(1): 17-24.
|
58. |
Frey PM, Méan M, Limacher A, et al. Physical activity and risk of bleeding in elderly patients taking anticoagulants. J Thromb Haemost, 2015, 13(2): 197-205.
|
59. |
Donzé J, Clair C, Hug B, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med, 2012, 125(8): 773-778.
|
60. |
Kämpfen P, Méan M, Limacher A, et al. Risk of falls and bleeding in elderly patients with acute venous thromboembolism. J Intern Med, 2014, 276(4): 378-386.
|
61. |
Klok FA, Dzikowska-Diduch O, Kostrubiec M, et al. Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J Thromb Haemost, 2016, 14(1): 121-128.
|
62. |
Matthews DT, Hemnes AR. Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension. Pulm Circ, 2016, 6(2): 145-154.
|
63. |
van Es J, den Exter PL, Kaptein AA, et al. Quality of life after pulmonary embolism as assessed with SF-36 and PEmb-QoL. Thromb Res, 2013, 132(5): 500-505.
|
64. |
Tavoly M, Utne KK, Jelsness-Jørgensen LP, et al. Health-related quality of life after pulmonary embolism: a cross-sectional study. BMJ Open, 2016, 6(11): e013086.
|
65. |
Kahn SR, Comerota AJ, Cushman M, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation, 2014, 130(18): 1636-1661.
|
66. |
Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation, 2014, 129(7): 764-772.
|
67. |
EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med, 2010, 363(26): 2499-2510.
|
68. |
EINSTEIN-PE Investigators, Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med, 2012, 366(14): 1287-1297.
|
69. |
Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med, 2013, 369(9): 799-808.
|
70. |
Hokusai-VTE Investigators, Büller HR, Décousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med, 2013, 369(15): 1406-1415.
|